Analysts Anticipate AVEO Pharmaceuticals, Inc. (AVEO) Will Announce Quarterly Sales of $740,000.00

Equities research analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce $740,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for AVEO Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $450,000.00 and the highest estimate coming in at $1.03 million. AVEO Pharmaceuticals reported sales of $1.03 million in the same quarter last year, which suggests a negative year-over-year growth rate of 28.2%. The firm is expected to report its next quarterly earnings results on Tuesday, May 14th.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year sales of $10.62 million for the current financial year, with estimates ranging from $2.00 million to $24.30 million. For the next financial year, analysts expect that the company will post sales of $18.18 million, with estimates ranging from $3.60 million to $30.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings data on Thursday, March 14th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $2.48 million.

A number of research firms recently weighed in on AVEO. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Tuesday, March 19th. HC Wainwright reissued a “hold” rating and issued a $1.00 price objective on shares of AVEO Pharmaceuticals in a research report on Monday, March 18th. FBR & Co set a $3.00 price objective on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 20th. BidaskClub raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Finally, Robert W. Baird assumed coverage on shares of AVEO Pharmaceuticals in a research note on Thursday, January 3rd. They issued an “outperform” rating and a $3.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $1.96.

In related news, major shareholder Equity Opportunities Fu Growth bought 4,347,827 shares of the company’s stock in a transaction on Monday, April 8th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $4,956,522.78. The purchase was disclosed in a filing with the SEC, which is available through this link. 4.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. NEA Management Company LLC grew its stake in AVEO Pharmaceuticals by 11.8% in the 4th quarter. NEA Management Company LLC now owns 20,896,038 shares of the biopharmaceutical company’s stock worth $33,434,000 after acquiring an additional 2,198,000 shares in the last quarter. BlackRock Inc. boosted its stake in shares of AVEO Pharmaceuticals by 3.3% during the fourth quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock valued at $11,773,000 after purchasing an additional 236,822 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of AVEO Pharmaceuticals by 1.5% during the third quarter. Vanguard Group Inc now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after purchasing an additional 73,519 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of AVEO Pharmaceuticals by 1.5% during the third quarter. Vanguard Group Inc. now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after purchasing an additional 73,519 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of AVEO Pharmaceuticals by 36.3% during the fourth quarter. Geode Capital Management LLC now owns 1,394,576 shares of the biopharmaceutical company’s stock valued at $2,231,000 after purchasing an additional 371,327 shares in the last quarter. Institutional investors and hedge funds own 35.72% of the company’s stock.

AVEO Pharmaceuticals stock traded down $0.09 during midday trading on Friday, reaching $1.01. The stock had a trading volume of 4,357,507 shares, compared to its average volume of 7,160,303. AVEO Pharmaceuticals has a 52-week low of $0.49 and a 52-week high of $3.59. The firm has a market capitalization of $140.39 million, a P/E ratio of -5.32 and a beta of 1.19.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Further Reading: What is the Gross Domestic Product (GDP)?

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.